| [iito] Business Intelligence. (May 2019). "Special Feature: What Does [iito] Stand For? A Powerful Business Database System, based on Property Rights Theory and Institutional Economics = [i]nstitutions [i]nformation [t]echnologies [o]rganisation!". Breme |
2019-05-30 |
| [iito] Business Intelligence. (April 2019). "Special Feature: [iito] Relaunches Life-Sciences-UK.com & Life-Sciences-France.com". Bremen. |
2019-04-17 |
| [iito] Business Intelligence. (April 2019). "Special Feature: [iito] Reaches New Milestone – Now more than 9,900 European Life Science Deals Available at Life-Sciences-Europe.com". Bremen. |
2019-04-26 |
| [iito] Business Intelligence. (9/29/11). "[iito]view – E-mail Interview with Pierre Legrain, Vice President of HUPO". Bremen. |
2011-09-29 |
| [iito] Business Intelligence. (9/15/10). "Press Release: [iito] Announces Milestones for Mass Spectrometry Web Portal »Mass-Spec-Capital.com«. Opens Newsletter Archives – Launches Own Editorial Content". Bremen. |
2010-09-15 |
| [iito] Business Intelligence. (7/8/19). "Press Release: [iito] Launches Life-Sciences-Benelux.com
& Life-Sciences-Scandinavia.com". Bremen. |
2019-07-08 |
| [iito] Business Intelligence. (7/1/19). "Press Release: Worldwide First! [iito] Does Away with All Tracking Cookies and Third Party Cookies". Bremen. |
2019-07-01 |
| [iito] Business Intelligence. (5/23/11). "Press Release: Launch of Life-Sciences-Germany.com – English-language Doorway to Life Sciences in German-speaking Europe". Bremen. |
2011-05-23 |
| [iito] Business Intelligence. (5/20/10). "Press Release: [iito] Launches Free Mass Spectrometry Newsletter. Premier Issue Right in Time for ASMS 2010 Meeting in Salt Lake City – New Service Is Based on the Web Portal www.Mass-Spec-Capital.com". Bremen. |
2010-05-20 |
| [iito] Business Intelligence. (3/5/10). "Press Release: Launch of New Mass Spectrometry Web Portal – Mass-Spec-Capital.com". Bremen. |
2010-03-05 |
| [iito] Business Intelligence. (3/24/11). "Press Release: [iito] Business Intelligence Enters Social Media with an Initial Focus on Twitter. Strategic Move Positions [iito] in the Up-to-the-Minute News Market for Mass Spectrometry as well as German and Eu |
2011-03-24 |
| [iito] Business Intelligence. (12/9/15). "Press Release: Life-Sciences-UK.com Launches Today. New Business Web Portal for the UK and Irish Life Sciences Targets Decision Makers World-wide". Bremen & London. |
2015-12-09 |
| [iito] Business Intelligence. (11/7/11). "Press Release: [iito] Completes Online B2B Offering with Launch of Free Newsletter for the European Life Sciences. Premier Issue of the [LSE] Newsletter Published Today". Bremen. |
2011-11-07 |
| [iito] Business Intelligence. (10/6/11). "Press Release: [iito] Launches Free Monthly Newsletter for the Life Sciences in Germany, Austria and Switzerland. Premier Issue of the [LSG] Newsletter Published Today". Bremen. |
2011-10-06 |
| [iito] Business Intelligence. (10/5/15). "Press Release: Life-Sciences-France.com Launches Today. New Business Web Portal for the French Life Sciences Targets Decision Makers Worldwide". Bremen & Paris. |
2015-10-05 |
| [iito] Business Intelligence. (10/4/12). "Press Release: [iito] Is Putting Privacy and Content First. Free [iito] Web Offerings Target Senior-level Managers in the Worldwide Life Sciences Industry". Bremen. |
2012-10-04 |
| [iito] Business Intelligence. (10/31/18). "Press Release: [iito] Discontinues Life-Sciences-Spain.com. All Data Will Still Be Available at Life-Sciences-Europe.com". Bremen. |
2018-10-31 |
| [iito] Business Intelligence. (10/11/11). "Press Release: Life-Sciences-Europe.com Launches Today. Business Web Portal for the European Life Sciences". Bremen. |
2011-10-11 |
| [iito] Business Intelligence. (1/11/19). "Press Release: [iito] Discontinues Life-Sciences-UK.com
and Life-Sciences-France.com. All Data Will Still Be Available at Life-Sciences-Europe.com". Bremen. |
2019-01-11 |
| Zytoprotec GmbH. (1/29/13). "Press Release: Zytoprotec Raises EUR 2 Million in Financing from Baxter Ventures". Vienna. |
2013-01-29 |
| Zivak Technologies. (10/3/13). "Press Release: Introduction of SPE9600 Automated 96-Well-Plate SPE System at Medica 2013 Fair". |
2013-10-03 |
| Zivak Technologies. (10/2/13). "Press Release: ZinMass Clinical LC-MS/MS Analyzer Will Be Exhibited at Medica 2013". |
2013-10-02 |
| Zeltia S.A.. (9/15/15). "Press Release: PharmaMar Opens New Affiliate in UK". Madrid. |
2015-09-15 |
| Zeltia S.A.. (11/7/12). "Press Release: PharmaMar Germany Commences Commercial Activity". Madrid. |
2012-11-07 |
| Zelluna Immunotherapy AS. (6/25/19). "Press Release: Zelluna Immunotherapy Appoints Jens-Peter Marschner as Chief Medical Officer". Oslo. |
2019-06-25 |
| Zellkraftwerk. (1/3/13). "Press Release: Zellkraftwerk Announces Early Access Program. Select Drug Developers to Obtain Pre-release Access to Groundbreaking Cellular Biomarker Discovery Platform". Hannover. |
2013-01-03 |
| Zedira GmbH. (9/22/15). "Press Release: Cooperation between Zedira and Cardiff University. Transglutaminase 6 Is the Focus of New Research into Ataxia". |
2015-09-22 |
| Zedira GmbH. (7/1/16). "Press Release: Dr. Falk Pharma GmbH and Zedira Enter a Phase 1b Clinical Trial for a Celiac Disease Drug". Freiburg & Darmstadt. |
2016-07-01 |
| Zedira GmbH. (6/25/12). "Press Release: Zedira, Dr. Falk Phama and the University of Mainz Hospital, which Together Comprise a Flagship Project of the CI3 Excellence Cluster, Are to Receive Subsidy Funding for Clinical Development of a Celiac Disease Dru |
2012-06-25 |
| Zedira GmbH. (5/2/17). "Press Release: Dr. Falk Pharma and Zedira Announce Completion of Phase 1b Clinical Trial of ZED1227 for the Treatment of Celiac Disease and Move on to Proof of Concept Study". Freiburg & Darmstadt. |
2017-05-02 |
| Zedira GmbH. (4/26/18). "Press Release: Dr. Falk Pharma and Zedira Announce Start of the Phase 2a Proof of Concept Study of ZED1227 for the Treatment of Celiac Disease". Freiburg & Darmstadt. |
2018-04-26 |
| Zedira GmbH. (3/2/15). "Press Release: Dr. Falk Pharma and Zedira Enter Phase I Clinical Trials for a Celiac Disease Drug". Freiburg & Darmstadt. |
2015-03-02 |
| Zedira GmbH. (2/3/15). "Press Release: Zedira Receives further Funding to Develop Factor XIIIa-blockers for Safe Anticoagulation". Darmstadt. |
2015-02-03 |
| Zedira GmbH. (11/30/16). "Press Release: Zedira Receives Funding by the German Government for the Development of Transglutaminase Inhibitors for the Treatment of Diabetic Nephropathy". Darmstadt. |
2016-11-30 |
| Zedira GmbH. (10/20/15). "Press Release: Zedira, Dr. Falk Pharma and the University of Mainz Hospital, which Together Comprise a Flagship Project of the Ci3 Leading-edge Cluster, Are to Receive Additional Subsidy Funding for Clinical Development of a Cel |
2015-10-20 |
| Zealand Pharma A/S. (9/3/13). "Press Release: Zealand Appoints New Chief Scientific Officer. Dr Torsten Hoffmann Joins from Roche". Copenhagen. |
2013-09-03 |
| Zealand Pharma A/S. (7/3/17). "Press Release: Zealand Initiates First Phase 3 Trial with Dasiglucagon for the Treatment of Severe Hypoglycemia in Diabetes". Copenhagen. |
2017-07-03 |
| Zealand Pharma A/S. (7/28/14). "Press Release: Zealand and Boehringer Ingelheim Sign Second Collaboration Agreement to Advance Novel Peptide Medicines". Copenhagen & Ingelheim. |
2014-07-28 |
| Zealand Pharma A/S. (6/16/11). "Press Release: Zealand Pharma and Boehringer Ingelheim Enter into a License and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity". Copenhagen & Ingelheim. |
2011-06-16 |
| Zealand Pharma A/S. (10/9/15). "Press Release: Zealand Meets Development Milestone in Collaboration with Boehringer Ingelheim". Copenhagen. |
2015-10-09 |
| Zavante Therapeutics, Inc.. (3/30/16). "Press Release: Zavante Therapeutics Closis $45 Million Series A Financing in Support of U.S. Development for a First-in-Class Injectable Antibiotic". San Diego, CA. |
2016-03-30 |
| Zavante Therapeutics, Inc.. (10/9/15). "Press Release: Zavante Announces New Company Formation and Initial Financing". San Diego, CA. |
2015-10-09 |
| Zambon Group. (7/25/19). "Press Release: Zambon Completes Transformational Acquisition of Breath Therapeutics". Milan. |
2019-07-25 |
| Yumab GmbH. (7/22/19). "Press Release: Yumab Announces New Research and Collaboration Agreement with Merck". Braunschweig. |
2019-07-22 |
| Yukin Therapeutics S.A.S.. (6/4/19). "Press Release: Yukin Therapeutics Raises €3.3 million to Develop New Cancer Treatments". Sophia Antipolis. |
2019-06-04 |
| Ysios Capital. (10/18/16). "Press Release: Ysios Capital Raises €126,4 m ($140 m) for Its Second Fund, Ysios Biofund II Innvierte". Barcelona. |
2016-10-18 |
| Ysios Capital Partners. (09/13/2011). "Press Release: Ysios Capital Partners Leads €29.2million Series D Financing of AM-Pharma". Barcelona. |
2011-09-13 |
| Xoma Corporation. (8/25/17). "Press Release: Xoma Announces Transformational License Agreements for Gevokizumab and Its IL-1 beta Intellectual Property Portfolio". Berkeley, CA. |
2017-08-25 |
| XL-protein GmbH. (7/26/17). "Press Release: Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation Technology to Develop Long-Acting Asparaginase Product Candidates". Freising. |
2017-07-26 |
| XL-protein GmbH. (6/25/13). "Press Release: XL-protein and Generium Sign Broad Therapeutic License and Collaboration Agreement to Develop PASylated Therapeuticas for the Russian Federation". Freising & Moscow. |
2013-06-25 |
| XL-protein GmbH. (4/18/13). "Press Release: High Yield with ESETEC and PASylation. Wacker Biotech and XL-protein Produce More than Four Grams per Liter of Fab Antibody Fragment with Prolonged Plasma Half-life". Munich, Jena & Freising. |
2013-04-18 |
| XL-protein GmbH. (2/12/15). "Press Release: XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals Using its PASylation Technology". Freising. |
2015-02-12 |
| XL-protein GmbH. (10/21/14). "Press Release: Yeda and XL-protein Sign Business Collaboration Agreement to Commercialize PASylated Interferon Superagonist". Freising & Rehovot. |
2014-10-21 |
| XL-protein GmbH. (1/9/18). "Press Release: Horizon Pharma plc and XL-protein GmbH Have Entered Into a Collaboration Agreement on a Potential Next-Generation Biologic for Uncontrolled Gout Using PASylation® Technology". Freising. |
2018-01-09 |
| Xigen S.A.. (1/5/17). "Press Release: Xigen’s Brimapitide, an Innovative JNK Inhibitor, Delivers Positive Phase II Results in Inflammatory Eye Disease". Geneva. |
2017-01-05 |
| Xenikos B.V.. (5/24/16). "Press Release: Xenikos B.V. to Introduce Immunotherapy T-Guard to Potential Pharmaceutical Partners at BIO International Convention 2016". Nijmegen. |
2016-05-24 |
| Xencor, Inc.. (4/4/12). "Press Release: Xencor Receives Second Milestone Payment from Boehringer Ingelheim under Antibody Technology License Agreement". Monrovia, CA. |
2012-04-04 |
| Xencor, Inc.. (2/5/19). "Press Release: Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech". Monrovia, CA. |
2019-02-05 |
| Xencor, Inc.. (1/7/19). "Press Release: Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody". Monrovia, CA. |
2019-01-07 |
| Xeltis. (12/2/14). "Press Release: Xeltis Closes Euro 27 Million / USD 34 Million Series B Financing". Zürich. |
2014-12-02 |
| Xeltis AG. (2/2/16). "Press Release: Xeltis Appoints New CFO". |
2016-02-02 |
| Xeltis AG. (12/17/15). "Press Release: Xeltis Extends Series B Financing to €30M, Signing off Transformational Year". Zurich. |
2015-12-17 |
| Xeltis AG. (11/15/17). "Press Release: Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs". Zurich & Eindhoven. |
2017-11-15 |
| Xeltis AG. (1/31/17). "Press Release: FDA Gives Xeltis Go Ahead to Begin Trials in the USA". |
2017-01-31 |
| X-Biotix Therapeutics, Inc.. (7/1/19). "Press Release: X-Biotix Therapeutics Joins Antimicrobials Working Group". Washington, DC. |
2019-07-01 |
| WuXi AppTec. (4/15/16). "Press Release: WuXi AppTec Acquires Crelux". Munich. |
2016-04-15 |
| Wise S.r.l.. (5/25/17). "Press Release: Wise Srl Raises EUR 6.5 Million for Clinical Validation of Novel Neuroelectrodes for Brain Monitoring and Spinal Cord Stimulation". Milan & Berlin. |
2017-05-25 |
| Wilex AG. (9/6/13). "Press Release: Nuclea Biotechnologies Inc. Acquires Wilex Inc. and Extends Their Cooperation with Wilex AG. Nuclea Purchased All Shares of Wilex Inc. (Oncogene Science)". Munich & Pittsfield, MA & Cambridge, MA. |
2013-09-06 |
| Wilex AG. (9/29/09). "Press Release: Preliminary Data of Mesupron Show Impressive Increase in Overall Survival of Patients with Pancreatic Cancer. Mesupron in Combination with Gemcitabine Shows Clear Improvement in Tumour Response as Well as Median Survi |
2009-09-29 |
| Wilex AG. (9/27/16). "Press Release: Subsidiary Heidelberg Pharma Contracts Suisse CDMO Celonic for Antibody Cell Line Development and Antibody Production". Munich. |
2016-09-27 |
| Wilex AG. (9/2/13). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs License Agreement for the Development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche". Munich. |
2013-09-02 |
| Wilex AG. (9/19/16). "Press Release: Wilex AG – Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center". Munich. |
2016-09-19 |
| Wilex AG. (9/1/09). "Press Release: Patient Recruitment in Phase III Registration Trial with Redectane Successfully Completed". Munich. |
2009-09-01 |
| Wilex AG. (8/7/13). "Press Release: Wilex Starts Clinical Phase I Trial with PI3K Inhibitor WX-037". Munich. |
2013-08-07 |
| Wilex AG. (8/4/10). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. |
2010-08-04 |
| Wilex AG. (8/17/10). "Press Release: Wilex AG. Mandatory Takeover Offer from dievini Hopp BioTech Has Ended". Munich. |
2010-08-17 |
| Wilex AG. (8/12/15). "Press Release: Wilex AG Announces Discontinuation of Collaboration between Its Subsidiary Heidelberg Pharma and Roche [Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)]". Munich. |
2015-08-12 |
| Wilex AG. (7/29/10). "Press Release: Wilex AG Recommends Shareholders Not to Accept the Mandatory Offer of dievini Hopp BioTech holding GmbH % Co. KG". Munich. |
2010-07-29 |
| Wilex AG. (7/2/13). "Press Release: Burrill Securities Supports Wilex in Exploring Financing Partners". Munich. |
2013-07-02 |
| Wilex AG. (7/19/10). "Press Release: Wilex AG Resolves Rights Issue Using Authorised Capital". Munich. |
2010-07-19 |
| Wilex AG. (7/15/14). "Press Release: Wilex Publishes Half-yearly Financial Report 2014". Munich. |
2014-07-15 |
| Wilex AG. (7/15/14). "Press Release: Wilex AG Successfully Completes Capital Reduction. Reverse 4:1 Share Split Reduces Number of Outstanding Shares from 31.3 Million to 7.8 Million". Munich. |
2014-07-15 |
| Wilex AG. (7/15/10). "Press Release: Wilex AG Receives Tender Offer for a Mandatory Takeover Bid by dievini Hopp BioTech holding". Munich. |
2010-07-15 |
| Wilex AG. (7/14/15). "Press Release: Wilex Publishes Half-yearly Financial Report". Munich. |
2015-07-14 |
| Wilex AG. (7/13/17). "Press Release: Wilex Reports on First Half-year". Munich. |
2017-07-13 |
| Wilex AG. (7/12/12). "Press Release: Wilex Announces Results of Successful First Half Year 2012". Munich. |
2012-07-12 |
| Wilex AG. (7/11/13). "Press Release: Wilex Publishes Half-yearly Financial Report 2013". Munich. |
2013-07-11 |
| Wilex AG. (7/10/13). "Press Release: UCB Gets Access to Rights for an Antibody Programme from Wilex for Non-oncology Indications". Munich & Brussels. |
2013-07-10 |
| Wilex AG. (6/2/16). "Press Release: Wilex AG Announces Change on the Executive Management Board". Munich. |
2016-06-02 |
| Wilex AG. (6/19/17). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates". Munich. |
2017-06-19 |
| Wilex AG. (6/14/12). "Press Release: Mesupron Met Its Primary Objective of Demonstrating Efficacy in the Proof of Concept Phase II Breast Cancer Trial". Munich. |
2012-06-14 |
| Wilex AG. (5/3/10). "Press Release: Final Phase II Data of Mesupron Confirm Impressive Increase in Overall Survival of Patients with Pancreatic Cancer". Munich. |
2010-05-03 |
| Wilex AG. (4/8/15). "Press Release: Wilex AG Successfully Completes Rights Issue". Munich. |
2015-04-08 |
| Wilex AG. (4/25/16). "Press Release: Wilex AG Successfully Completes Capital Increase". Munich. |
2016-04-25 |
| Wilex AG. (4/24/17). "Press Release: Wilex AG Plans Rights Issue Using Authorised Capital. Ad-hoc release [Not for distribution, publication or transmission in the USA, Canada, Japan and Australia]". Munich. |
2017-04-24 |
| Wilex AG. (4/14/14). "Press Release: Wilex Published 3-Month Financial Reports 2014". Munich. |
2014-04-14 |
| Wilex AG. (4/14/10). "Press Release: Wilex Publishes 3-Month Financial Report 2010 and Reports Improved Results for the Period". Munich. |
2010-04-14 |
| Wilex AG. (4/14/10). "Press Release: Presentation 3-Month Financial Report. 14 April 2010". Munich. |
2010-04-14 |
| Wilex AG. (4/12/17). "Press Release: Interim Management Statement on the First Three Months of 2017". Munich. |
2017-04-12 |
| Wilex AG. (4/12/12). "Press Release: Wilex Publishes Financial Report for the First Quarter of 2012. Rights Issue Successfully Concluded – Process for Final Analysis of Rencarex Started – Revenue and Earnings Improved". Munich. |
2012-04-12 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Source
![[iito] Business Intelligence – The Elephants Are Coming 560x91px](/banner/iito-20190816-650-091-youtube-video-the-elephants-are-coming-telegram.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
